Impact of a computer-assisted decision support system (CDSS) on nutrition management in critically ill hematology patients: the NUTCHOCO study (nutritional care in hematology oncologic patients and critical outcome)

Florence Ettori, Aurélia Henin, Christophe Zemmour, Laurent Chow-Chine, Antoine Sannini, Magali Bisbal, Frédéric Gonzalez, Luca Servan, Jean Manuel de Guibert, Marion Faucher, et al.

To cite this version:
Florence Ettori, Aurélia Henin, Christophe Zemmour, Laurent Chow-Chine, Antoine Sannini, et al.. Impact of a computer-assisted decision support system (CDSS) on nutrition management in critically ill hematology patients: the NUTCHOCO study (nutritional care in hematology oncologic patients and critical outcome). Annals of Intensive Care, 2019, 10.1186/s13613-019-0527-6. inserm-02363238

HAL Id: inserm-02363238
https://inserm.hal.science/inserm-02363238
Submitted on 14 Nov 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Impact of a computer-assisted decision support system (CDSS) on nutrition management in critically ill hematology patients: the NUTCHOCO study (nutritional care in hematology oncologic patients and critical outcome)

Florence Ettori1, Aurélia Henin1, Christophe Zemmour2,3, Laurent Chow-Chine1, Antoine Sannini1, Magali Bisbal1, Frédéric Gonzalez1, Luca Servan1, Jean Manuel de Guibert1, Marion Faucher1, Jean Marie Boher2,3 and Djamel Mokart1*

Abstract

Background: Mortality of critically ill hematology (HM) patients has improved over time. Thus, those patients require an extensive diagnostic workup and the optimal use of available treatments. There are no data regarding nutrition strategy for critically ill HM patients, while nutritional support is crucial for both HM and critically ill patients. We hypothesized that the implementation of a computer-assisted decision support system (CDSS), designed to supervise a nutritional intervention by a multidisciplinary team, would be able to increase guidelines adherence and outcomes.

Results: In this before/after study, 275 critically ill hematology patients admitted to the ICU over 5-year period were included. Energy and protein intakes were delivered using standard protocol in the 147 patients (53%) of the ‘before group’ and using a CDSS in order to reach every day predefined caloric and protein targets accordingly to the catabolic or anabolic status in the 128 patients (47%) of the ‘after group.’ Using a Poisson regression, we showed that the use of CDSS allowed to reach a relative increase in the rate of days in compliance with caloric (1.57; 95% confidence interval (CI), [1.17–2.10], p = 0.0025) and protein targets (3.86 [2.21–6.73], p < 0.0001) in the ‘after group’ by more than 50% as compared with the ‘before group.’ Interestingly, compliance rates were low and only reached 30% after intervention. Hospital mortality, ICU-acquired infection, and hospital, and ICU length of stay were similar in the two groups of patients. Importantly, exploratory analysis showed that hospital mortality was lower in the ‘after group’ for neutropenic and severely ill patients.

Conclusion: For critically ill hematology patients, the use of a nutritional CDSS allowed to increase the days in compliance with caloric and protein targets as compared with no CDSS use. In this context, overall hospital mortality was not affected.
Introduction
HM patients increasingly require admission to the intensive care unit (ICU) for life-threatening events related to the malignancy and/or treatments [1, 2]. The prognosis of HM patients has improved considerably over time, in fact mortality in HM patients septic shock has fallen by 30% [3], while in patients receiving invasive mechanical ventilation (IMV) improvement has resulted in a sharp drop in mortality, from nearly 90% to about 40% [4]. Thus, critically ill HM patients require an extensive diagnostic workup [5] and the optimal use of available treatments [6]. Nutritional support is crucial in critically ill patients. Guidelines recommend early enteral feeding supplying 25 kcal/kg per day during the acute phase of critical illness [7, 8] with however a low level of evidence. For HM patients treated with myeloablative conditioning for allogeneic stem cell transplantation, early nutritional intervention has proven a benefit on outcome and mortality outside the ICU [9]. There are no data regarding nutrition strategy for HM patients during ICU stay. As most of ICU therapies, nutritional support has become more complex requiring tight supervision and monitoring. Thus, computer-assisted decision support systems (CDSSs), designed to implement rational care strategies based on guidelines and pathways, have been developed and studied over the past several years [10]. For this study, we hypothesized that implementation of a CDSS, designed to actively supervise a nutritional intervention by a multidisciplinary team, would be able to increase guidelines adherence and outcomes.

Methods
Study periods
This retrospective ‘before/after’ cohort study was conducted over two time periods within 5 years totaling 3501 patient days in the ICU for 275 patients. The pre-interventional period (‘before period’) took place from November 2009 to March 2011, the post-interventional period (‘after period’) from November 2011 to November 2014. We compared two chronological cohorts: the ‘before group’ with unmonitored nutritional care and the ‘after group’ with updated nutritional care (computer assisted, guideline updated, immunonutrient supplemented). Patients and most of clinico-biological data were retrospectively identified and analyzed using our prospective ICU database included in our ICU information system (MetaVision®, iMDsoft, Tel Aviv, Israel). Following the ‘before period’, a CDSS module was locally designed and added to our ICU information system as a tool to provide clinicians with essential guideline-based information concerning nutritional support in the ICU and hematology patients [7, 11–13]. Details concerning the implementation of the nutrition protocols during the 2 periods are provided in the Additional file 1. The study was approved by the Paoli-Calmettes Institute institutional review board which waived the need for informed consent.

Aims of the study
By the use of CDDS, our primary objective was to demonstrate a significant increase in the number of days in compliance with calories target, defined as days on which caloric delivery fitted the target of 25 kcal/kg/day ± 15% during the aggression period, or 35 kcal/kg/day ± 15% during stable recovering periods, and in the number of days in compliance with protein target, defined as days on which protein delivery fitted a target of 1.5 g/kg/day ± 15%. Secondary clinical objectives were to assess the impact of the use of the CDSS on morbidity (ICU and hospital lengths of stay, duration of IMV, antimicrobial, renal replacement, and vasopressors treatments) and hospital survival for the overall patients, exploratory analysis was also realized for hematopoietic stem cell transplant (HSCT) recipients, neutropenic and severe patients defined as SAPS II > 56 on ICU admission [14–16]. Nutritional secondary objectives were to assess the impact of the use of the CDSS on cumulative days of enteral, parenteral, and total caloric and protein cumulative balance on day 3, day 5, and day of ICU discharge.

Targets and nutrition protocols
Protocols were based on ESPEN guidelines [7, 11–13] that were locally adapted and validated by the ICU staff. During the study periods, the energy target recommendation was 25 kcal/kg/day and 35 kcal/kg/day during acute illness and recovery period, respectively. Patients were categorized as in acute phase or recovery phase at the clinician’s opinion and corresponded to any of the following situations: ongoing vasopressor treatment, renal replacement therapy (RRT), IMV, sepsis, shock, etc. Recovery period was defined as stable clinical state which could include prolonged (> 48 h) stable ventilation periods. Ideal body weight was used for calculations in case of BMI > 30 kg/m² [17]. Protein recommendations were set at 1.5 g/kg/day. Enteral nutrition (EN) was used whenever possible, combined feeding when EN did not cover the prescribed target, and parenteral nutrition (PN) when EN was not feasible. Compliance with guidelines was evaluated for each patient each day of the ICU stay according to the recommended energy and protein targets. Intravenous energy was received from PN, as well as from non-nutritional energy sources (calculated by the CDSS which considered glucose, gluco-saline, or drug infusion, and fat from propofol). Daily protein delivery was also retrieved from the CDSS on days with artificial nutrition. Feeding routes were defined as PN, EN,
combined (EN and PN), and oral. Since our CDSS was
designed to only assist the EN and PN prescriptions,
oral intake was not taken into account for the primary
endpoints of the overall population. In addition, oral
alimentation is commonly difficult to realize in severe
hematology patients (ARF, septic shock, mucositis,
HSCT recipient), thus we assume the oral intakes to be
negligible in those situations.

Feeding products are described in Additional file 2.

ICU management
Our medical institution is a tertiary care reference center
for cancer patients. Patients admitted to the ICU ben-
efit from a daily close collaboration between their refer-
ing hematologists and ICU-appointed intensivists. All
consecutive patients suffering from a hematologic neo-
plasia were included at 48 h of ICU. Pregnant women,
minors, patients admitted for, or switched within the
first 48 h to palliative ICU care, patients discharged alive
within the first 48 h were not included. Reasons for ICU
admission were recorded based on the main symptoms
at ICU admission. Acute respiratory failure was defined
as oxygen saturation less than 90% or PaO₂ less than
60 mmHg on room air combined with severe dyspnoea
at rest with an inability to speak in sentences or a respira-
tory rate greater than 30 breaths per minute or clinical
signs of respiratory distress [5]. Shock was defined as
previously reported [16]. Mild malnutrition was defined
as total weight loss >5% and ≤ 10% usual body weight
over the last 6 months and severe malnutrition as weight
loss >10%. Life-supporting interventions, anti-infectious
agents, prophylactic treatments, urate oxidase use, and
diagnostic procedures were administered at the discre-
tion of the attending intensivists, who followed best
clinical practice and guidelines. Chemotherapy, corti-
costeroids, hematopoietic growth factors, immunosup-
pressive drugs, and other cancer-related treatments were
prescribed by the hematologist in charge of each patient
in accordance with institutional guidelines. Etiologic
diagnoses were made by consensus by the intensivists,
 hematologists, and consultants, according to recent de-
definitions [1].

Clinical and biological data
All clinical and biological data were prospectively col-
lected, except for caloric and protein balances in the ‘before group’; however, for this group, intakes were
prospectively computed by our medical system informa-
tion. The following clinical data were collected during the
ICU stay (Table 1), among them: age and gender; height;
weight; calorie and protein intakes; caloric and protein
deficit at day 3, day 5, and ICU discharge; the number
of days in compliance with caloric and protein targets
during ICU stay; loss of weight at ICU discharge; char-
acteristics of the malignancy; neutropenia (absolute neu-
троophil count of <0.5 × 10⁹ l⁻¹); characteristics of sepsis;
chronic health status as evaluated using the Knaus scale
[18]; severity-of-illness scores using Simplified Acute
Physiology Score II (SAPS II) [19] at admission, cause of
ICU admission; therapeutic interventions in ICU, includ-
ing vasopressor use, need, and duration of IMV, RRT,
antimicrobial treatment; ICU and hospital length of stay;
and hospital mortality. Organ failures as defined as a
SOFA score of ≥ 3 for any system [20].

Statistical analysis
Individual data collected prior to ICU were summarized
using counts (frequencies) for qualitative variables and
medians [25th–75th percentiles] or means [standard
deviations (SD)] for quantitative variables. The primary
objective was to compare the number of days in com-
pliance with calories target between the study cohorts
enrolled prior and after initiation of CDSS intervention,
respectively. Analysis of the primary endpoint was per-
formed using Poisson regression including terms for
cohort (after vs. prior CDSS) and length of ICU stay as
an offset term to account for individual duration of expo-
sure. A multivariate regression was then performed to
confirm the results, by adding as covariates neutropenic,
severe and allogeneic SCT statuses. Estimate of intensity
rate ratio (IRR) derived from Poisson regression was used
to assess the difference in the number of days in compli-
ance between the two cohorts. Correction for over dis-

dispersion in variance estimation was used to derive robust
95% confidence intervals for IRR. Similar analyses were
performed for the number of protein compliant days,
treatment days IMV, vasopressors, RRT, and antibiot-
ics. Exploratory similar analyses of the number of caloric
and protein compliant days were also performed in neu-
tropenic, severe and allogeneic HSCT patients, respect-
ively; in order to account for multiple comparisons, a
Bonferroni correction was applied to these analyses and
the level of significance was set to 0.05/6 = 0.008. In each
cohort, cumulative incidences of death during ICU stay
were estimated using the Prentice’s method by consid-
ering patient alive at ICU discharge as a competing risk
and compared using Gray’s tests. Other secondary end-
points were compared across the two groups of patients
by using Chi-square or Fisher’s exact tests for qualitative
variables, and Wilcoxon rank-sum tests for quantitative
variables.

A total of 252 patients was initially planned in this
study (126 in each cohort). This sample size was deter-
mined using Cook’s formula to a detect a 50% increase
in the primary endpoint using CDSS (IRR=1.5) with
95% power and 5% error risk, assuming equal period of
Table 1  Characteristics of the population

|                                | Before group (n = 147) | After group (n = 128) | p value |
|--------------------------------|------------------------|-----------------------|---------|
| Sex (female)                   | 63 (43)                | 48 (37)               | 0.37    |
| Age (years)                    | 58 [46–66]             | 60 [52–68]            | 0.14    |
| Height (cm)                    | 170 [164–175]          | 170 [165–175]         | 0.33    |
| Weight at ICU admission (kg)   | 75 [63–83]             | 73 [65–87]            | 0.32    |
| Weight at ICU discharge (kg)   | 70.00 [59–80]          | 70.00 [60–82]         | 0.84    |
| Weight loss at ICU discharge (kg) | 1.00 [0.00–3.00]       | 0.00 [–0.50–2.00]     | 0.53    |
| BMI                            | 24 (21–28)             | 24 (22–27)            | 0.84    |
| Nutritional status             |                        |                       |         |
| No or Mild malnutrition        | 119 (81)               | 95 (74)               | 0.18    |
| Severe malnutrition            | 27 (19)                | 33 (26)               | 0.14    |
| Oral alimentation at ICU discharge | 92 (63)               | 75 (59)               | 0.50    |
| SAPSII score                   | 46 [36–59]             | 48.50 [40–58]         | 0.38    |
| Severe patients (SAPSII > 56)  | 41 (28)                | 40 (31)               | 0.54    |
| Comorbidities                  |                        |                       |         |
| Cardiovascular                 | 46 (31)                | 47 (37)               | 0.34    |
| Respiratory                    | 37 (25)                | 42 (33)               | 0.73    |
| Hepatic                        | 8 (5)                  | 5 (4)                 | 0.55    |
| Renal                          | 11 (7)                 | 5 (4)                 | 0.21    |
| Neurologic                     | 11 (7)                 | 8 (6)                 | 0.69    |
| Diabetes                       | 16 (11)                | 12 (9)                | 0.70    |
| Hematology disease             |                        |                       |         |
| AML                            | 56 (38)                | 35 (27)               | 0.06    |
| ALL                            | 18 (12)                | 4 (3)                 | 0.006   |
| Lymphoma                       | 40 (27)                | 50 (39)               | 0.04    |
| Myeloma                        | 17 (12)                | 14 (11)               | 0.87    |
| Autologous SCT                 | 27 (18)                | 30 (23)               | 0.30    |
| Allogeneic SCT                 | 32 (22)                | 38 (30)               | 0.13    |
| Neutropenia                    | 43 (29)                | 57 (45)               | 0.009   |
| CML, CLL                       | 16 (11)                | 25 (20)               | 0.04    |
| Complete remission             | 43 (34)                | 31 (24)               | 0.1     |
| Main cause for ICU admission   |                        |                       |         |
| ARF                            | 50 (34)                | 56 (44)               | 0.1     |
| Shock                          | 48 (33)                | 35 (27)               | 0.36    |
| AKI                            | 18 (12)                | 6 (5)                 | 0.03    |
| Neurologic failure             | 11 (7)                 | 15 (12)               | 0.23    |
| Others                         | 20 (14)                | 16 (12)               | 0.79    |
| Organ support                  |                        |                       |         |
| IMV                            | 72 (49)                | 59 (46)               | 0.72    |
| Vasopressors                   | 83 (56)                | 72 (56)               | 1       |
| RRT                            | 32 (22)                | 35 (27)               | 0.32    |
| ICU length of stay (days)      | 11 (13)                | 14 (13)               | 0.06    |
| Hospital mortality             | 72 (49)                | 54 (42)               | 0.28    |
| Hospital length of stay (days) | 38 (41)                | 37 (28)               | 0.94    |

AKI acute kidney injury, ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, ARF acute respiratory failure, BMI body mass index, CLL chronic lymphocytic leukemia, CML chronic myelogenous leukemia, HSCT hematopoietic stem cell transplantation, ICU intensive care unit, IMV invasive mechanical ventilation, RRT renal replacement therapy, SAPSII Simplified acute physiology score
accreditation in each cohort; an expected length of stay in ICU of 7 days, an intensity rate of 0.40 in the first cohort and a default value for over dispersion parameter (φ = 1).

All statistical analyses were performed using the Statistical Analysis System (SAS), version 9.3 (SAS Institute Inc, Cary, NC, USA).

Results

Clinical parameters (Table 1)

Two hundred seventy-five patients were included in the present study, 147 (53%) in the ‘before group’ and 128 (47%) in the ‘after group.’ Clinical characteristics of patients are presented in Table 1. Briefly, age was 59 years [49–67] and SAPSII score was 47 [37–59]. Main comorbidities were cardiovascular disease for 34% (n = 93) of subjects, respiratory 29% (n = 79), hepatic 5% (n = 13), renal 6% (n = 16), neurological 7% (n = 19), and diabetes mellitus 10% (n = 28). Regarding hematological malignancy, 113 (41%) patients presented with acute leukemia, 90 (33%) with lymphoma and 41 (15%) with chronic leukemia. At ICU admission, 100 (36%) patients were neutropenic, 70 (25%) and 57 (21%) patients benefited from allogeneic and autologous HSCT, respectively. One hundred six (38%) patients presented with ARF and 83 (30%) with shock. During ICU stay, 131 (48%) patients required IMV, 155 (56%) vasopressors and 67 (24%) RRT. Hospital mortality was 46% (n = 126).

Nutritional parameters

Regarding energy delivery (Table 2), during the ICU stay the rate of days in compliance with caloric target had improved in the ‘after group’ by a 10% absolute increase and 50% relative increase in percentage of energy target reached as compared with the ‘before group’ (28.8% [24.6–33.7%] vs. 18.4% [14.4–23.5%]; IRR = 1.57; 95% confidence interval (CI), [1.17–2.10], p = 0.0025). This effect was confirmed in multivariate analysis (28.3% [24.0–33.5%] vs. 20.0% [15.6–25.7%], IRR = 1.42 [1.05–1.94], p = 0.02). We did not observe this trend in neutropenic, severe, or HSCT patients (Table 2). In accordance, daily calories intake was significantly higher in the ‘after group’ as compared with the ‘before group’ (Additional file 3: Table S1). Between the two periods, the rate of days with PN significantly increased (IRR = 1.29 [1.10–1.52], p = 0.0021), while a non-significant trend was described for EN (IRR = 1.90 [0.98–3.66], p = 0.056) as well as for combined nutrition (EN + PN) (Additional file 4: Table S2). A specific nutritional focus on day 3 established that only three (2%) patients benefited from EN in the ‘before group’ vs 15 (12%) patients in the ‘after group,’ p = 0.002 (Additional file 5: Table S3). For these patients, enteral calories intakes were 624 (443) kcal versus 914 (615) kcal (p = 0.37) at day 3, and 685 (558) kcal versus 779 (581) kcal (p = 0.63) at day 5, for the ‘before’ and ‘after’ groups, respectively (Additional file 5: Table S3). During these first three days of ICU stay, 14 patients (11%) did not benefit from any EN, whereas 99 patients (77%) were treated with inefficient EN (enteral and/or oral quantities lower than 500 kcal), among them 87 (88%) had a justified medical reason for this enteral feeding failure. Of the 114 patients for whom an EN was initiated at ICU admission, enteral intolerance was diagnosed

Table 2 Number of days reaching caloric and protein targets during ICU stay

|                | ‘Before group’ | ‘After group’ | Intensity rate ratio | p     |
|----------------|---------------|---------------|---------------------|-------|
|                | Number of days in ICU days within target | Intensity rate | Number of days in ICU days within target | Intensity rate |
| All patients   | n = 147       | 2.08 (4.29)   | 18.4% [14.4–23.5%] | 4.13 (6.13) | 28.8% [24.6–33.7%] | 1.57 [1.17–2.10] | 0.0025 |
| Calories       | 0.83 (3.09)   | 7.3% [4.3–12.5%] | 4.09 (5.55) | 28.3% [24.4–32.8%] | 3.86 [2.21–6.73] | <0.0001 |
| Protins        | n = 43        | 2.28 (4.04)   | 23.4% [15.2–36.0%] | 5.33 (6.53) | 33.7% [27.4–41.5%] | 1.44 [0.89–2.33] | 0.13  |
| Neutropenic    | n = 41        | 2.00 (3.26)   | 20.9% [13.6–32.0%] | 3.75 (4.01) | 26.1% [20.2–33.8%] | 1.25 [0.76–2.07] | 0.38  |
| Severe patients| n = 32        | 2.56 (3.72)   | 23.6% [15.5–35.8%] | 4.42 (4.62) | 29.8% [23.8–37.4%] | 1.27 [0.79–2.04] | 0.33  |
| Allogeneic HSCT| n = 147       | 1.47 (4.65)   | 13.5% [5.2–34.9%] | 4.34 (5.00) | 29.3% [22.4–38.4%] | 2.17 [0.81–5.82] | 0.12  |

Significant results are represented in italic after Bonferroni correction

HSCT hematopoietic stem cell transplantation
in 49 patients (43%). During the first three days of ICU stay, only 30 (22%) patients benefited from PN in the ‘before group’ versus 88 (69%) patients in the ‘after group’ ($p<0.0001$). For these patients, PN calories intakes were $1217 (469)$ kcal versus $1488 (587)$ kcal ($p=0.028$) at day 3, and $1306 (505)$ kcal versus $1444 (560)$ kcal ($p=0.18$) at day 5, for the ‘before’ and ‘after’ groups, respectively (Additional file 5: Table S3). During the first 5 days of ICU admission, the number of patients who did not receive neither PN nor EN was significantly lower in the ‘after group’ as compared with the ‘before group’ ($p<0.0001$) (Additional file 5: Table S3). During the ICU stay, cumulative caloric deficit significantly decreased in the ‘after group’ as compared with the ‘before group’ (Additional file 1: Table S1). In addition, the number of underfed patients (daily deficit greater than 500 kcal) was significantly more important in the ‘before group’ versus the ‘after group’: 119 (86%) patients versus 41 (32%) on day 3, and 76 (67%) versus 24 (20%) on day 5, respectively (Additional file 1: Table S1). At ICU discharge, weight loss was similar between the two groups ($p=0.53$) (Table 1). Overfeeding (excess calories of the day > 500 kcal) was similar between the two groups, on day 3, eight patients (6.25%) were overfed in the ‘after group’ versus 3 (2.17%) ($p=0.12$) in the ‘before group’, and 14 patients (11.67%) versus 5 (4.42%) ($p=0.06$) on day 5 (Additional file 1: Table S1).

Regarding protein delivery (Table 2), during the ICU stay, the rate of days in compliance with protein target relatively increased in the ‘after group’ by more than 50% as compared with the ‘before group’ (7.3% [4.3–12.5%] vs. 28.3% [24.4–32.8%]; IRR = 3.86 [2.21–6.73], $p<0.0001$). By considering Bonferroni correction, this trend was also significant in severe patients (Table 2). Days with IMV, vasopressors treatment, RRT, antibiotics, ICU-acquired infection, and organ failures regardless of neutropenia were similar between the two groups of patients (Table 3). Hospital death cumulative incidences were similar for the two nutritional strategies in overall population (Fig. 1) and in the subgroup of allogeneic HSCT. Conversely, hospital survival was significantly higher in the ‘after group’ compared to the ‘before group’ for neutropenic ($p=0.018$), and severe patients ($p=0.023$). Interestingly, SAPSII score was similar at ICU admission between ‘before group’ and ‘after group’ for neutropenic patients (53.00 [43.00–63.00] vs. 56.00 [46.00–65.00], $p=0.45$, respectively) and severe patients (68.00 [61.00–75.00] vs. 64.50 [60.00–71.50], $p=0.18$, respectively).

### Table 3 Outcomes during ICU stay

| Support                     | ‘Before group’ (n = 147) | ‘After group’ (n = 128) | Intensity rate ratio [CI 95%] | p     |
|-----------------------------|--------------------------|-------------------------|-------------------------------|-------|
| Intensity rate              |                          |                         |                               |       |
| Days with IMV               | 3.99 (7.45)              | 4.83 (8.89)             | 0.96 [0.71–1.30]              | 0.79  |
| Days with vasopressors      | 2.76 (4.16)              | 2.56 (3.35)             | 0.74 [0.53–1.02]              | 0.07  |
| Days with dialysis          | 1.06 (2.67)              | 2.06 (4.72)             | 1.54 [0.90–2.63]              | 0.12  |
| Days with antibiotics       | 8.90 (7.85)              | 12.38 (11.34)           | 1.10 [0.97–1.26]              | 0.14  |
| Number of antibiotics used  | 3.07 (1.86)              | 3.52 (2.03)             | 0.91 [0.73–1.12]              | 0.37  |
| during ICU stay             |                          |                         |                               |       |
| Infections                  |                          |                         |                               |       |
| ICU-acquired infection      | 34 (23.13)               | 40 (31.25)              | 0.13                          |       |
| VAP                         | 18 (12.24)               | 16 (12.50)              | 0.95                          |       |
| Bacteremia                  | 12 (8.16)                | 18 (14.06)              | 0.12                          |       |
| CVC-related infection       | 4 (2.72)                 | 4 (3.13)                | 1                             |       |
| Urinary tract infection     | 5 (3.40)                 | 8 (6.25)                | 0.27                          |       |

*IMV invasive mechanical ventilation, ICI intensive care unit, VAP ventilation associated pneumonia, CVC central venous catheter*
Discussion

We report herein, in this before/after study, on 275 critically ill hematology patients admitted to the ICU over a 5-year period. Energy and protein intakes were delivered using standard protocol in the 147 patients (53%) of the ‘before group’ and using a CDSS in order to reach every day predefined caloric and protein targets accordingly to the catabolic or anabolic status in the 128 patients (47%) of the ‘after group’. We showed that the use of CDSS allows to relatively increase the rate of days in compliance with caloric and protein targets in the ‘after group’ by more than 50% as compared with the ‘before group’. Interestingly, compliance rates were low and only reached 30% after intervention. Hospital mortality, ICU-acquired infection, and hospital and ICU length of stay were similar in the two groups of patients. Exploratory analysis showed that hospital mortality was lower in the ‘after group’ for neutropenic and severely ill patients.

In critically ill patients, guidelines recommend the use of early EN during the acute phase of the disease in order to prevent muscle wasting, infections, delayed recovery, and mortality [7, 8]. However, early EN may induce vomiting and gut ischemia during septic shock [21]. In hematology patients and in allogeneic HSCT recipients, guidelines recommend the use of early EN since it seems to be associated with better survival, less acute graft-versus-host disease (GVHD), and faster neutrophil recovery as compared with PN [11, 12, 22]. One striking finding from our study is that EN was difficult to realize in critically ill hematology patients, in fact the rate of EN days during ICU stay was low and about 15% and 25% for the before and after groups, respectively (Additional file 2: Table S2). The use of CDSS was however significantly helpful in this setting, particularly in the first 5 days of ICU admission during which only 4% of patients were nourished using EN before the use of CDSS and 26% after (Additional file 3: Table S3). We showed that the causes of EN failure could be frequently related to specific hematologic clinical patterns such as colitis or mucositis (Fig. 2). For these reasons, PN seemed to be the more appropriate feeding route as PN represented about 50% (‘before group’) of nutrition intakes during ICU stay and significantly increased to 63% (Additional file 2: Table S2). Accordingly, during the first 5 days of ICU admission, PN was the most frequent feeding route and the rate of patients nourished with PN significantly increased to 76% after CDSS use (Additional file 3: Table S3). Early nutrition appeared to be a crucial appointment in our study since 45% (‘after group’) and 58% (‘before group’) of the total caloric deficit was reached during the first 5 days of ICU admission (Additional file 1: Table S1). Thus, during the same period and after CDSS use, the number of patients who benefited from early nutrition (PN and/or EN) significantly increased as well as caloric intake (Additional file 3: Table S3). CDSS seemed to be an interesting tool to optimize energy intake and limit energy deficit in this setting [10, 23–25]. Our results are in line with recent randomized clinical trials in which early PN was safe and as effective as enteral route which was associated with gastrointestinal complications [21, 26]. In NUTRI-REA-2 study [21], caloric target was designed to match the course of acute disease in two steps (the acute and the recovery phases) [27], we used similar design for energy delivery. Despite this strategy, our patients were underfed due to the low compliance rate regarding energy target only reaching the value of 30% even after CDSS use. Similar results were found in the CALORIES study [26] in which the percentage of patients in whom energy target was met was about 30% for each day of the study period. Taken together, these results underline that energy intake might be better evaluated with daily rather than global assessment in which underfeeding might be underestimated. Indeed, in our study, the mean daily calorie intake in the ‘after group’ was comparable to recent data [28], about 1200 kcal/day (Additional file 1: Table S1), suggesting a moderate underfeeding contrasting with a more profound underfeeding when the assessment was detailed every day. Importantly, the low rate of compliance regarding caloric target was also due to overfeeding situations, thus 12% of patients were overfed at day 5 in the ‘after group’ (Additional file 1: Table S1). Finally, the failure to reach caloric target might be overestimated...
since the number of days in compliance with calories target was defined as days on which caloric delivery fitted the targets ±15%. This definition appears to be very strict as compared with recent studies in which underfeeding was defined as caloric intake below 70% of the target [29].

There is growing evidence that protein intake might also affect outcomes [30, 31]; however, the best protein intake in critically ill patients is still unknown. Recent recommendations on protein intake for critically ill patients are only based on studies with a low level of evidence [32]. In the present study, we showed that the use of CDSS was associated with both a significant increase in protein delivery and decrease in protein deficit during ICU stay. Thus, mean daily protein intake after intervention was about 56 g/day (Additional file 1: Table S1) and similar to that recently described by Nicolo et al. [28]. As for energy intake, 47% (‘after group’) and 52% (‘before group’) of the total protein deficit was reached during the first 5 days of ICU admission (Additional file 1: Table S1) underlining once again the potent crucial role of early PN for those patients. Intensivists usually focus on caloric rather than protein goals, and the parenteral nutrition products we used have compositions that could not provide 1.5 g of protein/kg/day without overfeeding. Thus, prescribers needed to trade off between high calories or high proteins. Glutamine, added to total PN, could be a key to higher protein delivery without a caloric overshoot [33]. During the ‘after period,’ glutamine was available in our institution and thus integrated in the CDSS and could have allowed us to better reach our protein targets.

The hospital mortality was about 46% consistent with recent results [1]. For the overall population, CDSS use did not translate into a mortality benefit. Because mortality was a secondary objective, our sample was not powered to show significant mortality difference. However, exploratory analysis showed a significant effect on hospital outcome after CDSS use for the neutropenic and severe patients but not for HSCT recipients. Interestingly, SAPSII score was similar at ICU admission between ‘before group’ and ‘after group’ for neutropenic and severe patients. These results should be interpreted cautiously nevertheless they reinforce the hypothesis of a beneficial effect on outcome of using CDSS. After intervention, we described in severe patients, a significant increase in days within protein target, while this effect was not retrieved for calories target. Taken together, these results suggest that protein intake in critically ill hematology patients might be a crucial step of ICU management. Indeed, it has been recently shown in critically ill patients that if the basal amount of protein is provided, restricted calories intake did not impact on outcome [29]. Recent data have also shown in patients who remained in the ICU ≥4 days and achieved at least 80% of prescribed protein intake a lower mortality than those achieving <80% of prescribed. In this situation, percentage of prescribed energy intake was not associated with outcomes [28]. Whether reciprocal relationships exist between calorie and protein intakes exist in severe hematology patients remains to be determined.

Our study presents several limitations. First, the distinction between the acute phase and the recovery period was based on the clinician’s choice. Because there is no consensus on the definitions of acute phase and recovery phase, the retrospective analysis of the clinician’s evaluation might have led to significant variability from one patient to another. Such variability might have influenced the results. Second, due to the retrospective nature of the study, we were unable to collect the causes of non-use of enteral nutrition among the 14 patients who did not benefit. However, the causes of failure of enteral nutrition are detailed Fig. 2. Third, we did not plan to collect cases of refeeding syndrome; however, in our daily practice, these cases are rare, whereas the ICU admission of severely malnourished patients was relatively frequent (22%).

In conclusion, we showed that the use of CDSS allows to increase relatively the rate of days in compliance with caloric and protein targets by more than 50%. Interestingly, compliance rates were low and only reached 30% after intervention. Hospital mortality, ICU-acquired infection and lengths of stay were similar in the two groups.

Acknowledgements
None.

Authors’ contributions
DM and FE contributed to the design of the work and were involved in the acquisition, analysis, and interpretation of data, and drafted the manuscript; CZ and JMB contributed to the acquisition and analysis of data and drafted the manuscript; LCC and AS contributed to the acquisition of data and revision of the manuscript; MB and GF contributed to the analysis of data and revision of the manuscript; LS, JMD, and MF contributed to the analysis of data and design of the work and was involved in interpretation of data and revision of the manuscript. All authors read and approved the final manuscript.

Additional files
Additional file 1. Implementation of the nutrition protocols during the 2 periods.
Additional file 2. Description of feeding products during the study period.
Additional file 3: Table S1. Intakes and cumulative deficit for calories and proteins during ICU stay.
Additional file 4: Table S2. Type of nutrition during ICU stay.
Additional file 5: Table S3. Route and caloric intake during the five first days of ICU admission.
Funding
The study was partly funded by limited grant from Fresenius Kabi, France.

Availability of data and materials
The original datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study was approved by the Paoli-Calmettes Institute Institutional Review Board, and since there was no interference with patients’ management, signed informed consent was waived.

Consent for publication
Not applicable.

Competing interests
All authors declare no competing interests. Fresenius Kabi was not involved in any aspect of the design or conduct of the study, the data analysis, or the manuscript preparation and presentation.

Author details
1 Intensive Care Unit, Department of Anesthesiology and Critical Care, Institut Paoli-Calmettes, 232 Boulevard de Sainte Marguerite, 13009 Marseille Cedex 09, France. 2 Unité de Biostatistique et de Méthodologie, Institut Paoli-Calmettes, Marseille, France. 3 INSERM, IRD, SESSTIM, Aix Marseille Université, Marseille, France.

Received: 13 January 2019   Accepted: 27 April 2019

Published online: 07 May 2019

References
1. Azoulay E, Mokart D, Pene F, Lambert J, Koutatch A, Mayaux J, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium—a groupe de recherche respiratoire en reanimation onco-hematologique study. J Clin Oncol. 2013;31:2810–8.
2. Tavares M, Lemiale V, Mokart D, Pene F, Lengline E, Koutatch A, et al. Determinants of 1-year survival in critically ill acute leukemia patients: a GRRR-OH study. Leuk Lymphoma. 2018;59:1323–31.
3. Zuber B, Tran TC, Aegerter P, Grimaldi D, Charpentier J, Guidet B, et al. Impact of case volume on survival of septic shock in patients with malignancies. Crit Care Med. 2012;40:55–62.
4. Azoulay E, Pichkis P, Soares M, Perner A, Rello J, Bauer PR, et al. Acute hypoxic respiratory failure in immunocompromised patients: the Efaim multinational prospective cohort study. Intensive Care Med. 2017;43:1808–19.
5. Azoulay E, Mokart D, Lambert J, Lemiale V, Rabitat A, Koutatch A, et al. Diagnostic strategy for hematology and oncology patients with acute respiratory failure: randomized controlled trial. Am J Respir Crit Care Med. 2010;182:1038–46.
6. Azoulay E, Pene F, Darmon M, Lengline E, Benoist D, Soares M, et al. Managing critically ill hematologic patients: time to think differently. Blood Rev. 2015;29:359–67.
7. Kreymann KG, Berger MM, Deutz NE, Hiesmayr M, Jolliet P, Kazandjiev G, et al. ESPEN guidelines on enteral nutrition: intensive care. Clin Nutr. 2006;25:210–23.
8. McClave SA, Taylor BE, Martindale RG, Warren MM, Johnson DR, Braunschweig C, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.N.). JPEN J Parenter Enteral Nutr. 2016;40:159–211.
9. Seguy D, Duhamel A, Rejeb MB, Gomez E, Buhl ND, Bruno B, et al. Better outcome of patients undergoing enteral tube feeding after myeloablative conditioning for allogeneic stem cell transplantation. Transplantation. 2012;94:267–94.
10. Dvir D, Cohen J, Singer P. Computerized energy balance and complications in critically ill patients: an observational study. Clin Nutr. 2006;25:37–44.
11. Arends J, Bodoky G, Bozzetti F, Feunon K, Muscaritoli M, Selga G, et al. ESPEN guidelines on enteral nutrition: non-surgical oncology. Clin Nutr. 2006;25:245–59.
12. Bozzetti F, Arends J, Lundholm K, Mickiewright A, Zurcher G, Muscaritoli M. ESPEN guidelines on parenteral nutrition: non-surgical oncology. Clin Nutr. 2009;28:445–46.
13. Singer P, Berger MM, van den Berghe G, Biolo G, Calder P, Forbes A, et al. ESPEN guidelines on parenteral nutrition: intensive care. Clin Nutr. 2009;28:387–400.
14. Mokart D, Sannini A, Brun JP, Faucher M, Blaise D, Blache JL, et al. N-terminal pro-brain natriuretic peptide as an early prognostic factor in cancer patients developing septic shock. Crit Care. 2007;11:R37.
15. Mokart D, Saillard C, Zemmour C, Bidal M, Sannini A, Chow-Chine L, et al. Early prognostic factors in septic shock cancer patients: a prospective study with a proteomic approach. Acta Anaesthesiol Scand. 2018;62:493–503.
16. Mourad M, Chow-Chine L, Faucher M, Sannini A, Brun JP, de Guibert JM, et al. Early diastolic dysfunction is associated with intensive care unit mortality in cancer patients presenting with septic shock. Br J Anaesth. 2014;112:102–9.
17. Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome: N Engl J Med. 2000;342:1301–8.
18. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. Prognosis in acute organ-system failure. Ann Surg. 1985;202:685–93.
19. Jr Le Gall, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957–63.
20. Vincent JL, Moreno R. Clinical review: scoring systems in the critically ill. Crit Care. 2010;14:207.
21. Reignier J, Boissire-Helms J, Brisard L, Lascarrou JB, Alt HA, Anguel N, et al. Enteral versus parenteral early nutrition in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group study (NUTRIREA-2). Lancet. 2018;391:133–43.
22. Baumgartner A, Bargetzi A, Zueger N, Bargetzi M, Medinger M, Bounoure L, et al. Revisiting nutritional support for allogeneic hematologic stem cell transplantation—systematic review. Bone Marrow Transpl. 2017;52:506–13.
23. Berger MM, Que YA. Bioinformatics assistance of metabolic and nutrition management in the ICU. Curr Clin Nutr Metab Care. 2011;14:202–8.
24. Conseil M, Carr J, Molinari N, Ciosev Y, Cisse M, Belafa F, et al. A simple widespread computer help improves nutrition support orders and decreases infection complications in critically ill patients. PLoS ONE. 2013;8:e63771.
25. Heidegger CP, Berger MM, Graf S, Zingg W, Darmon P, Costanza MC, et al. Optimum of energy provision with supplemental parenteral nutrition in critically ill patients: a randomised controlled clinical trial. Lancet. 2013;381:385–93.
26. Harvey SE, Parrott F, Harrison DA, Bear DE, Segaran E, Beale R, et al. Trial of the route of early nutritional support in critically ill adults. N Engl J Med. 2014;371:1675–84.
27. Preiser JC, van Zanten AR, Berger MM, Biolo G, Casarà MP, Doig GS, et al. Metabolic and nutritional support of critically ill patients: consensus and controversies. Crit Care. 2015;19:35.
28. Nicolo M, Heyland DK, Chittams J, Sammarco T, Compfer C. Critical outcomes related to protein delivery in a critically ill population: a multicenter, multinational observation study. JPN J Parenter Enteral Nutr. 2016;40:45–51.
29. Arabi YM, Aikawa AS, Haddad SH, Al-Dorzi HM, Tammim HM, Jones G, et al. Permissive underfeeding or standard enteral feeding in critically ill adults. N Engl J Med. 2015;372:2398–408.
30. Wejs PJ, Wilschmeyer PE. Optimizing energy and protein balance in the ICU. Curr Opin Clin Nutr Metab Care. 2013;16:194–201.
31. van Zanten AR. Should we increase protein delivery during critical illness? JPN J Parenter Enteral Nutr. 2016;40:756–62.
32. Hoffer LJ, Bistrian BR. Appropriate protein provision in critical illness: a systematic and narrative review. Am J Clin Nutr. 2012;96:591–600.
33. Wernecke J. How to understand the results of studies of glutamine supplementation. Crit Care. 2015;19:385.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.